BIO Adopts Principles on Workplace Development, Diversity, and Inclusion; Launches Board WDDI Committee

Washington, DC (June 19, 2017) – Today, the Biotechnology Innovation Organization (BIO) released a set of principles on workforce development, diversity, and inclusion (WDDI) for the biotechnology industry.  Concurrent with the adoption of these principles, BIO established a board-level WDDI Committee charged with working to foster workforce development, diversity, and inclusion at BIO and throughout the biotech industry.  The Committee will be chaired by Helen Torley, President & CEO of Halozyme, who is succeeding Julie Gerberding, Executive Vice President & Chief Patient Officer at Merck, who led the Committee as it developed BIO’s WDDI principles over the last year.

BIO Elects John Maraganore, Ph.D., as New Chair

A new slate of officers and Board members were elected during the 2017 BIO International Convention.

BIO Comments to FDA on Genome Editing in New Plant Varieties Used for Foods

BIO appreciates this opportunity to provide comments to the Food and Drug Administration (FDA) on its request for comments on genome editing in plants.

BIO Comments to USDA on its 340 Biotech Rules

BIO is pleased to submit these comments in response to the USDA Animal and Plant Health Inspection Service’s (APHIS’) request for public input on the proposed revisions to its biotechnology regulations in 7 CFR Part 340.

Media Advisory: Bioscience Job Creation Through Smart State Policies

Release of report detailing state legislative best practices in support of bioscience jobs, investments and innovation.

Media Advisory: University Research is Key Driver of National Economy

New report demonstrates the enormous financial and jobs impact from patent licensing of university research, known as tech transfer. Real-world examples of success from the University of California System and Stanford University will be shared.

Vonnie Estes to Receive 2017 Rosalind Franklin Award

BIO announced that biotech industry veteran Vonnie Estes will receive the 4th annual Rosalind Franklin Award for Leadership in Industrial Biotechnology on Tuesday July 25, 2017, during a lunch plenary session of the 2017 BIO World Congress on Industrial Biotechnology.

Patient Engagement: BIO Comments FDA Docket "Enhancing Patient Engagement Efforts Across FDA"

The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on Enhancing Patient Engagement Efforts Across the Food and Drug Administration.

BIO IES: Advanced Biofuel RVP EPW Letter 170612

BIO IES: Advanced Biofuel RVP EPW letter 170612